A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
Recruiting now · Phase 1
Conditions studied: Advanced Solid Tumors
In brief
This is a Phase I/Ib first-in-human, open-label, non-randomized, multicenter, multi-country study to evaluate the safety and tolerability and to establish a recommended Phase 2 dose (RP2D) as well as assess preliminary clinical activity of ABX-001 administered intravenously (IV) alone (Part A) or co-administered with pembrolizumab (Part B) in participants with refractory/relapsed advanced solid tumors.
Key facts
- Study ID
- NCT07231458
- Run by
- Abalos Therapeutics GmbH
- People needed
- 27
- Starts
- 2025-10-14
- Expected to finish
- 2026-10-30
- Last updated by the study team
- 2026-01-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Charite-Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF) — Berlin, Germany (enrolling)
- Universitaetsklinikum Tuebingen — Tübingen, Germany (enrolling)
- Vall d'Hebron Institut d'Oncologia — Barcelona, Spain (enrolling)
- Hospital Universitario Fundacion Jimenez Diaz — Madrid, Spain (enrolling)
- The START Center for Cancer Care - CIOCC — Madrid, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.